Plasma MMP–2 and MMP–9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation

Summary

Uncontrolled activation of matrix metalloproteinases (MMPs) can result in tissue injury and inflammation, yet little is known about the activation of MMPs during orthotopic liver transplantation (OLT). OLT is associated with increased fibrinolytic activity due to elevated plasmin generation. The serine-protease plasmin not only causes degradation of fibrin clots but is also thought, amongst others, to play a role in the activation of some matrix metalloproteinases. We therefore studied the evolution of MMP-2 and -9 plasma concentrations during OLT and the effect of serine-protease inhibition by aprotinin on the level and activation of these MMPs. In a group of 24 patients who participated in a randomized, double-blind, placebo-controlled study we determined serial MMP-2 and MMP-9 plasma levels during transplantation using ELISA (total MMP), activity assays (activatable MMP) and zymography. In addition, the MMP-inhibitors TIMP-1 and TIMP-2 were assessed by ELISA. The putative regulating factors tumor necrosis factor alpha (TNF-α) and tissue-type plasminogen activator (t-PA) were assessed as well. Patients were administered high-dose aprotinin, regular-dose aprotinin or placebo during surgery. Plasma TIMP-1, TIMP-2 and MMP-2 level gradually decreased during transplantation. Approximately twothirds of total MMP-2 appeared to be in its activatable proMMP form. No release of MMP-2 from the graft could be detected. In contrast, plasma levels of MMP-9 increased sharply during the anhepatic and postreperfusion periods. Peak MMP-9 levels of about eight times above baseline were found at 30 minutes after reperfusion. Most MMP-9 appeared to be in its active/inhibitorcomplexed form. No significant differences were observed between the three treatment groups. However, in patients with more severe ischemia/reperfusion (I/R) injury the MMP-9 concentration, particularly of the active/inhibitor-complexed form, remained high at 120 minutes postreperfusion compared to patients with no or mild I/R injury. The decrease in plasma levels of MMP-2,TIMP-1 and TIMP-2 during OLT occurred irrespective of the severity of the I/R injury. There was a significant correlation between MMP-9 and t-PA levels, but not with TNF-α. In conclusion, OLT is associated with a sharp increase of MMP-9 during the anhepatic and postreperfusion periods, which coincided with the changes in t-PA. MMP-2, TIMP-1 and TIMP-2 gradually decreased during OLT. The composition of these MMPs was not altered by the use of aprotinin, suggesting that serine–protease/plasmin-independent pathways are responsible for MMP regulation during OLT. In addition, only MMP-9 seems to be involved in I/R injury during human liver transplantation.

Keywords

Aprotinin - ischemia/reperfusion injury - liver transplantation - matrix metalloproteinases - plasmin

• References

• 1 Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-70.
• 2 Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-33.
• 3 Kuyvenhoven JPh, van Hoek B, Blom E. et al. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various liver diseases and hepatocellular carcinoma. Thromb Haemost 2003; 89: 718-25.
• 4 Upadhya AG, Harvey RP, Howard TK. et al. Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat. Hepatology 1997; 26: 922-8.
• 5 Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology 1998; 28: 281-5.
• 6 Upadhya GA, Strasberg SM. Glutathione, lactobionate, and histidine: cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions. Hepatology 2000; 31: 1115-22.
• 7 Dzik WH, Arkin CF, Jenkins RL. et al. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1988; 71: 1090-5.
• 8 Legnani C, Palareti G, Rodorigo G. et al. Protease activities, as well as plasminogen activators, contribute to the “lytic” state during orthotopic liver transplantation. Transplantation 1993; 56: 568-72.
• 9 Porte RJ, Bontempo FA, Knot EA. et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978-84.
• 10 Porte RJ, Bontempo FA, Knot EA. et al. Tissue-type-plasminogen-activator-associated fibrinolysis in orthotopic liver transplantation. Transplant Proc 1989; 21: 3542.
• 11 Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-36.
• 12 Parks WC, Mecham RP. Matrix metalloproteinases. San Diego: Academic Press; 1998
• 13 Baramova EN, Bajou K, Remacle A. et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157-62.
• 14 Lijnen HR, Silence J, Lemmens G. et al. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost 1998; 79: 1171-6.
• 15 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61.
• 16 Porte RJ, Molenaar IQ, Begliomini B. et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000; 355: 1303-9.
• 17 Porte RJ. Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin Thromb Hemost 1993; 19: 191-6.
• 18 Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-38.
• 19 Klar E, Angelescu M, Zapletal C. et al. Definition of maximum cold ischemia time without reduction of graft quality in clinical liver transplantation. Transplant Proc 1998; 30: 3683-5.
• 20 Gveric D, Hanemaaijer R, Newcombe J. et al. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001; 124: 1978-88.
• 21 Hanemaaijer R, Visser H, Konttinen YT. et al. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren’s syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998; 17: 657-65.
• 22 Sier CF, Casetta G, Verheijen JH. et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000; 06: 2333-40.
• 23 Capper SJ, Verheijen J, Smith L. et al. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay. Ann N Y Acad Sci 1999; 878: 487-90.
• 24 Sier CF, Kubben FJGM, Ganesh S. et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-17.
• 25 Molenaar IQ, Legnani C, Groenland THN. et al. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transplant 2001; 07: 896-903.
• 26 Montaner J, Alvarez-Sabin J, Molina C. et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-66.
• 27 Kai H, Ikeda H, Yasukawa H. et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
• 28 Sopata I, Dancewicz AM. Presence of a gelatin-specific proteinase and its latent form in human leucocytes. Biochim Biophys Acta 1974; 370: 510-23.
• 29 Opdenakker G, van den Steen PE, Dubois B. et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-9.
• 30 Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001; 56: 729-32.
• 31 Nakamura T, Ebihara I, Shimada N. et al. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998; 316: 355-60.
• 32 Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 1431-42.
• 33 Yano M, Omoto Y, Yamakawa Y. et al. Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 2001; 20: 679-86.
• 34 Cursio R, Mari B, Louis K. et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinases inhibitor. FASEB J 2002; 16: 93-5.
• 35 Falk V, Soccal PM, Grunenfelder J. et al. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur J Cardiothorac Surg 2002; 22: 53-8.
• 36 Boeker KHW, Haberkorn CI, Michels D. et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71-81.
• 37 Murawaki Y, Ikuta Y, Koda M. et al. The proMMP-2 activation rate in patients with chronic viral liver disease. Clin Chim Acta 2002; 324: 99-103.
• 38 Baricos WH, Cortez SL, el Dahr SS. et al. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP2 cascade. Kidney Int 1995; 47: 1039-47.
• 39 Selzner N, Rudiger H, Graf R. et al. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-36.